VEXT Science, Inc.

CSE:VEXT United States Healthcare — Drug Manufacturers - Specialty & Generic

Vext Science, Inc., through its subsidiaries, provides integrated agricultural technology, services, and property management services in the cannabis industry in the United States. It owns and manages cultivation facilities, manufacturing u…

Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the full company research view.
Results 2026-05-21
Vext Reports Q1 2026 Financial Results; Adjusted EBITDA up 73% Sequentially to $3.6 Million as Ohio Platform Scales
News release - English.pdf
Results 2026-05-21
Interim MD&A - English.pdf
Results 2026-05-21
Interim financial statements/report – English.pdf
News 2026-05-15
Vext Engages Zuanic & Associates
News release - English.pdf
Results 2026-04-29
Annual MD&A - English.pdf
Results 2026-04-29
Audited annual financial statements – English.pdf
Results 2026-04-29
Vext Reports Q4 and FY 2025; Fiscal 2025 Revenue up +43% to $51.4M, Operating Cash Flow up +256% to $11.7M as Ohio Retail Scales
News release - English.pdf
Transactions 2026-04-09 M&A
Vext Science, Inc. Announces Strategic Optimization of Arizona Cultivation Operations and Planned Expansion of Ohio Cultivation Operations
Material change report - English.pdf
Transactions 2026-03-30 M&A
Vext Science Announces Strategic Optimization of Arizona Operations and Plans for Ohio Cultivation Expansion
News release - English.pdf
News 2026-03-03
Vext Advances Ohio Expansion with Seventh Retail Location
News release - English.pdf
News 2026-01-03
Early warning report.pdf
Ownership 2026-01-02
Early Warning News Release of Jason T. Nguyen
News release - English.pdf
Results 2025-12-16
CORRECTION FROM SOURCE: Vext Reports Q3 2025 Financial Results
News release - English.pdf
Results 2025-11-21 Financials
Interim MD&A (amended) - English.pdf
Results 2025-11-20 Financials
Interim MD&A - English.pdf
Results 2025-11-20 Financials
Interim financial statements/report – English.pdf
Results 2025-11-20
Vext Reports Q3 2025 Financial Results; Revenue Up 41% Year-over-Year and Operating Cash Flow Year-To-Date Reaches $8.5 Million
News release - English.pdf
News 2025-11-14
Other.pdf
News 2025-11-11
News release - English.pdf
News 2025-09-17
News release - English.pdf
News 2025-08-20
News release - English.pdf
Results 2025-08-20 Financials
Interim MD&A - English.pdf
Results 2025-08-20 Financials
Interim financial statements/report – English.pdf
News 2025-08-11
News release - English.pdf
News 2025-06-26
Statement of executive compensation (form 51-102F6) - English.pdf
News 2025-06-24
News release - English.pdf
News 2025-06-16
News release - English.pdf
News 2025-06-05
Notice.pdf
News 2025-06-05
Letter from successor auditor.pdf
News 2025-06-05
Letter from former auditor.pdf
News 2025-06-05
News release - English.pdf

Showing 31 of 52 items in this period.